Intriguingly, most of the TRAIL-sensitive triple-negative breast cancer cell lines have mutated or lost p53 [30,95] which implies that TRAIL death receptor agonists may overcome the intrinsic chemotherapy resistance in TNBC deficient in p53. This evidence concerns the gene TNFSF10 and triple-negative breast carcinoma.